NPPA simplifies rules to ensure no stents shortage to patients
NPPA said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with its price cap order - a move seen as an attempt to simplify the process ensure continuation of cardiac services to patients. Viswanath Pilla Moneycontrol Bureau Indian drug price regulator National Pharmaceutical Pricing Authority (NPPA) in a notification on Friday said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with cap order. The move is being percieved as an attempt to simplify the procedure to ensure continuation of cardiac services to patients. NPPA's announcement comes amidst media reports of manufacturers and importers are withdrawing stents from the market holding up cardiac service delivery to patients.
“It is suggested that such price lists may be issued by e-mail, so as to reach dealers and retailers quickly,” said AK Khurana, director (pricing) of NPPA in the latest memo. Khurana asked the manufacturers to follow electronic submission of such price list through integrated pharmaceutical database management system (IPDMS) of the NPPA a proof thereof. NPPA on Thursday wrote to all chief secretaries to ensure compliance of stents price capping, its availability and uninterrupted cardiac care services, and directed the states and Centre to urge manufacturers to maintain production, import and supplies of stents at the precap level. NPPA also opened up new helpline – 1800111255 for citizens to register complaints regarding prices and supply and availability of coronary stents.
The regulator also asked citizens to file complaints of price non-compliance or shortage on its website through Pharma Jan Samadhan. NPPA has capped the prices of bare metal stent at Rs 7,260 and drug-eluting stent (DES) and biodegradable stents at Rs 29,600. Both the prices are exclusive of value added tax. DES constitutes 95 percent of the market. The steep price-cuts and immediate implementation of the notification by NPPA has caused quite a heartburn to stent manufacturers who sought at least 45 days time from the drug price regulator to comply with the order that involves relabeling MRP prices of stents with distributors and retailers. Some manufacturers even issued veiled threat that this could lead to supply disruption.
Read more for Indian Stock Tips- http://bit.ly/ace_services
NPPA said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with its price cap order - a move seen as an attempt to simplify the process ensure continuation of cardiac services to patients. Viswanath Pilla Moneycontrol Bureau Indian drug price regulator National Pharmaceutical Pricing Authority (NPPA) in a notification on Friday said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with cap order. The move is being percieved as an attempt to simplify the procedure to ensure continuation of cardiac services to patients. NPPA's announcement comes amidst media reports of manufacturers and importers are withdrawing stents from the market holding up cardiac service delivery to patients.
“It is suggested that such price lists may be issued by e-mail, so as to reach dealers and retailers quickly,” said AK Khurana, director (pricing) of NPPA in the latest memo. Khurana asked the manufacturers to follow electronic submission of such price list through integrated pharmaceutical database management system (IPDMS) of the NPPA a proof thereof. NPPA on Thursday wrote to all chief secretaries to ensure compliance of stents price capping, its availability and uninterrupted cardiac care services, and directed the states and Centre to urge manufacturers to maintain production, import and supplies of stents at the precap level. NPPA also opened up new helpline – 1800111255 for citizens to register complaints regarding prices and supply and availability of coronary stents.
The regulator also asked citizens to file complaints of price non-compliance or shortage on its website through Pharma Jan Samadhan. NPPA has capped the prices of bare metal stent at Rs 7,260 and drug-eluting stent (DES) and biodegradable stents at Rs 29,600. Both the prices are exclusive of value added tax. DES constitutes 95 percent of the market. The steep price-cuts and immediate implementation of the notification by NPPA has caused quite a heartburn to stent manufacturers who sought at least 45 days time from the drug price regulator to comply with the order that involves relabeling MRP prices of stents with distributors and retailers. Some manufacturers even issued veiled threat that this could lead to supply disruption.
Read more for Indian Stock Tips- http://bit.ly/ace_services
No comments:
Post a Comment